Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 475 of 3499 entries
View as:

Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00022659 Org: User:
Start: 04/30/02 End: 03/31/10 Due: 03/31/11

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03388619 Org: User:
Start: 01/17/18 End: 12/08/25 Due: 12/08/26

Testing the FLASHE Survey

Phase: N/A Priority: Normal
NCT ID: NCT01661036 Org: User:
Start: 07/23/12 End: 08/07/15 Due: 08/07/16

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Phase: N/A Priority: Normal
NCT ID: NCT03382574 Org: User:
Start: 03/14/19 End: 10/22/21 Due: 10/22/22

Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00054535 Org: User:
Start: 01/31/03 End: 09/30/04 Due: 09/30/05

Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT00047879 Org: User:
Start: 10/31/02 End: 06/30/09 Due: 06/30/10

Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00079170 Org: User:
Start: 01/31/04 End: 10/31/07 Due: 10/31/08

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00005842 Org: User:
Start: 06/30/00 End: - Due: -

VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide

Phase: N/A Priority: Normal
NCT ID: NCT00369590 Org: User:
Start: 08/31/06 End: 10/31/12 Due: 10/31/13

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Phase: N/A Priority: Normal
NCT ID: NCT01273181 Org: User:
Start: 12/31/10 End: 12/31/12 Due: 12/31/13

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Phase: N/A Priority: Normal
NCT ID: NCT00005576 Org: User:
Start: 01/31/01 End: - Due: -

Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00019916 Org: User:
Start: 06/30/00 End: 07/31/06 Due: 07/31/07

A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00062933 Org: User:
Start: 06/30/03 End: 03/31/08 Due: 03/31/09

Study of Lymphoma in Asia

Phase: N/A Priority: Normal
NCT ID: NCT01584141 Org: User:
Start: 07/05/11 End: 07/10/18 Due: 07/10/19

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00118183 Org: User:
Start: 07/31/05 End: - Due: -

Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

Phase: N/A Priority: Normal
NCT ID: NCT00002643 Org: User:
Start: 04/30/95 End: - Due: -

Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03253744 Org: User:
Start: 07/05/18 End: 02/16/25 Due: 02/16/26

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04633239 Org: User:
Start: 07/02/21 End: 11/01/25 Due: 11/01/26

Molecular Epidemiology of Cutaneous Malignant Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00341991 Org: User:
Start: 11/01/01 End: 06/26/20 Due: 06/26/21

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

Phase: N/A Priority: Normal
NCT ID: NCT00112736 Org: User:
Start: 04/30/05 End: 04/30/14 Due: 04/30/15

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

Phase: N/A Priority: Normal
NCT ID: NCT03253679 Org: User:
Start: 01/16/19 End: 10/31/22 Due: 10/31/23

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00349206 Org: User:
Start: 04/30/06 End: 02/29/12 Due: 02/28/13

Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT05907746 Org: User:
Start: 11/29/23 End: 07/31/31 Due: 07/31/32

Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT01610570 Org: User:
Start: 05/10/12 End: 05/21/14 Due: 05/21/15

Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00082966 Org: User:
Start: 03/31/04 End: - Due: -